[go: up one dir, main page]

FI931801A7 - HI-viruksen replikaation peptidi-inhibiittorit - Google Patents

HI-viruksen replikaation peptidi-inhibiittorit Download PDF

Info

Publication number
FI931801A7
FI931801A7 FI931801A FI931801A FI931801A7 FI 931801 A7 FI931801 A7 FI 931801A7 FI 931801 A FI931801 A FI 931801A FI 931801 A FI931801 A FI 931801A FI 931801 A7 FI931801 A7 FI 931801A7
Authority
FI
Finland
Prior art keywords
virus replication
peptide inhibitors
peptide
inhibitors
replication
Prior art date
Application number
FI931801A
Other languages
English (en)
Swedish (sv)
Other versions
FI931801A0 (fi
FI931801L (fi
Inventor
Martin Sumner-Smith
Richard W Barnett
Lorne S Reid
Nahum Sonenberg
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Publication of FI931801A7 publication Critical patent/FI931801A7/fi
Publication of FI931801A0 publication Critical patent/FI931801A0/fi
Publication of FI931801L publication Critical patent/FI931801L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI931801A 1990-10-24 1991-10-23 Peptid-inhibitorer av hi-virusreplikation FI931801L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60295390A 1990-10-24 1990-10-24
PCT/CA1991/000378 WO1992007871A1 (en) 1990-10-24 1991-10-23 Peptide-based inhibitors of hiv replication

Publications (3)

Publication Number Publication Date
FI931801A7 true FI931801A7 (fi) 1993-04-21
FI931801A0 FI931801A0 (fi) 1993-04-21
FI931801L FI931801L (fi) 1993-04-21

Family

ID=24413440

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931801A FI931801L (fi) 1990-10-24 1991-10-23 Peptid-inhibitorer av hi-virusreplikation

Country Status (11)

Country Link
EP (1) EP0554284B1 (fi)
JP (1) JPH06501938A (fi)
AT (1) ATE146483T1 (fi)
AU (1) AU660947B2 (fi)
CA (1) CA2092075A1 (fi)
DE (1) DE69123754T2 (fi)
DK (1) DK0554284T3 (fi)
ES (1) ES2095959T3 (fi)
FI (1) FI931801L (fi)
GR (1) GR3022838T3 (fi)
WO (1) WO1992007871A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
AU4037793A (en) * 1992-04-23 1993-11-29 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2152387C (en) * 1992-12-22 1998-10-27 Michael Twist (Deceased) Synergistic anti-viral compositions
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
AU685862B2 (en) * 1993-10-22 1998-01-29 Allelix Biopharmaceuticals Inc. Treatment of cytomegalovirus infection
US5627194A (en) * 1993-11-17 1997-05-06 Allelix Biopharmaceuticals Inc. Anti-viral guanidino-substituted compounds
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6258774B1 (en) * 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2003507438A (ja) 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
CA2458677A1 (en) * 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
ATE461708T1 (de) * 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
BRPI0608091A2 (pt) 2005-03-03 2009-11-10 Revance Therapeutics Inc composições e processos para aplicação tópica e distribuição transdérmica de um oligopeptìdeo
EP1861112A4 (en) 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
CA2629499A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
CA2764164A1 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
MX2015002465A (es) 2012-08-31 2015-11-06 Univ North Carolina Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3756789A (en) * 1988-06-16 1990-01-12 St. Louis University Antagonists of viral transactivating proteins

Also Published As

Publication number Publication date
EP0554284B1 (en) 1996-12-18
WO1992007871A1 (en) 1992-05-14
AU660947B2 (en) 1995-07-13
FI931801A0 (fi) 1993-04-21
DE69123754T2 (de) 1997-04-03
JPH06501938A (ja) 1994-03-03
ATE146483T1 (de) 1997-01-15
ES2095959T3 (es) 1997-03-01
CA2092075A1 (en) 1992-04-25
FI931801L (fi) 1993-04-21
AU8725991A (en) 1992-05-26
DE69123754D1 (de) 1997-01-30
GR3022838T3 (en) 1997-06-30
DK0554284T3 (da) 1997-01-06
EP0554284A1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
FI931801A7 (fi) HI-viruksen replikaation peptidi-inhibiittorit
FI941398A0 (fi) Modifioituja peptidijohdannaisia
FI925103A7 (fi) Ihmisen immuunipuutosviruksen antisense-inhibiittorit
NO914666L (no) Fjerning av trialkylarsiner
FI951379L (fi) Biohajoavista kopolymeereistä koostuvia mikrohiukkasvalmisteita
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
DE69220382D1 (de) Verwendung von Peptidderivaten
FI923280A0 (fi) Aminosubstituerade piperazinderivat.
DK181389A (da) Injektionsformer af gyraseinhibitorer
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
GB2259705B (en) Polypeptide inhibitor of viral replication
DE69117266D1 (de) Modifizierung von gelatine
DK273089D0 (da) Anvendelse af peptidderivater
NO940190D0 (no) Anvendelse av x-ketoglutarat
DK104489D0 (da) Anvendelse af triazolderivater
EP0833668A4 (en) INHIBITATION OF THE HEPATITIS B VIRUS REPLICATION
DK82592D0 (da) Fremstilling af proteiner
FI932554A7 (fi) Almokalantin kiinteitä annostusmuotoja ja menetelmiä niiden valmistami seksi
NO914349L (no) Fremgangsmaate for fremstilling av esterinhibitorer
DK120689D0 (da) Komplekser af selen- og tellurderivater
FI973277A0 (fi) Farmaseuttisia valmisteita TNF:n estämiseksi
MX24596A (es) Derivado de 1-piridilimidazol y procedimiento parasu preparacion.
FI932479L (fi) Rekombinant-insekt-virus med minskad kapacitet foer vaerd-till-vaerd-transmission i omgivningen och metoder foer framstaellning av detta virus
DE69218215D1 (de) Entfernung von schwefelwasserstoff
NO920025L (no) Synergime av hiv-reverstranskriptaseinhibitorer

Legal Events

Date Code Title Description
FD Application lapsed